Dr. Anagnostou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4940 Eastern Avenue
Baltimore, MD 21224Phone+1 410-550-0100Fax+1 410-550-0101
Summary
- I am a translational cancer investigator who is focusing on large-scale genomic, multi-omic and liquid biopsy
analyses in human cancers. My research is particularly focused on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. My team's long term goal is to transform medical oncology to molecular oncology, where treatment decisions are tailored not only to a baseline genotype but are also informed by real-time dynamics of liquid biopsies.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2010 - 2013
- University of AthensClass of 2005
Certifications & Licensure
- MD State Medical License 2013 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC Start of enrollment: 2020 May 26
- Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection Start of enrollment: 2023 Jan 27
Publications & Presentations
PubMed
- SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors.Theron Palmer, Michael D Kessler, Xiaoshan M Shao, Archana Balan, Mark Yarchoan
Cancer Research Communications. 2024-12-01 - Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15 - 2 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Journal Articles
- Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful ActivityElad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
Press Mentions
- Immunotherapy: Researchers Identify Ways to Help Predict Outcomes for Cancer TreatmentFebruary 14th, 2023
- A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is Associated with Immunotherapy ResponseFebruary 6th, 2023
- ‘Hard to Lose’ Mutations in Tumors May Predict Response to ImmunotherapyJanuary 26th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: